Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - search.ebscohost.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2022 - europepmc.org
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong, H Watanabe… - 2022 - documentserver.uhasselt.be
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca… - European heart …, 2023 - pubmed.ncbi.nlm.nih.gov
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - Eur. heart …, 2022 - pesquisa.bvsalud.org
AIMS: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - boris.unibe.ch
AIMS The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - EUROPEAN HEART …, 2022 - iris.hunimed.eu
Aims: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca… - European heart …, 2023 - yonsei.elsevierpure.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …